AOD-9604 vs L-Carnitine: Fat Release vs Fat Transport, the Human Evidence, Cost, and Which One Fits

AOD-9604 is a synthetic copy of the last fifteen amino acids of human growth hormone, positions 177 to 191, with a tyrosine added at the front: a 16-amino-acid peptide, the same molecule sold as "hGH fragment 176-191". AOD stands for Anti-Obesity Drug. It came out of Monash University in Melbourne and was developed in the late 1990s by Metabolic Pharmaceuticals as an oral obesity treatment. It is not growth hormone and not a secretagogue: cell work reports it does not bind the growth hormone receptor, and IGF-1 did not change in the human trials. The full reference is at what is AOD-9604.

• The "lipolytic domain" idea. A 2000 paper in Hormone Research proposed that growth hormone's fat effect lives in its tail end, separable from its growth and blood-sugar effects; obese Zucker rats on the fragment gained less weight and their fat tissue showed increased lipolytic activity.
• Beta-3 adrenergic receptors. A 2001 paper in Endocrinology reported the effect in obese mice depended on the beta-3 receptor, a fat-cell receptor that drives fat breakdown.
• Fat oxidation and glycerol release. A 2001 paper in the International Journal of Obesity reported increased fat oxidation and plasma glycerol, a marker of fat cells releasing their contents, in obese mice.

The FDA's 2024 review noted that the molecular target has never been identified.

Six randomised, placebo-controlled trials in Australia between roughly 2001 and 2007, close to 900 people. The intravenous studies reported a rise in circulating free fatty acids within hours of a dose, but no significant weight loss over the few weeks involved. The largest trial, OPTIONS, gave 536 adults with obesity oral AOD-9604 or placebo daily for 24 weeks alongside a supervised diet and exercise program, and did not find statistically significant weight loss versus placebo; the company ended development for obesity in February 2007. Safety findings were clean: no IGF-1 change, no impairment of glucose tolerance, no antibodies detected in the subjects tested. No trial used the subcutaneous injection that is prescribed.

L-carnitine is not a peptide and not a hormone. It is a small quaternary ammonium compound that the liver and kidneys make from the amino acids lysine and methionine, and most of the body's supply sits in skeletal and heart muscle. Its job is narrow and well characterised: it carries long-chain fatty acids across the inner mitochondrial membrane so they can be oxidised. Only the L form is biologically active, which is why the approved drug is called levocarnitine. The full reference is at what is L-carnitine.

• The carnitine shuttle. The enzyme CPT1 attaches a fatty acid to carnitine on the outer mitochondrial membrane, a transporter carries it through, and CPT2 releases it inside for oxidation. This is the rate-limiting step in long-chain fat oxidation.
• Buffering during hard exercise. A 2007 review in the Journal of Physiology described free carnitine soaking up excess acetyl groups as acetyl-carnitine, limiting lactate build-up.
• Muscle fuel selection, in humans. A 2011 Journal of Physiology study gave fourteen healthy men oral L-carnitine with carbohydrate twice daily for 24 weeks, with muscle biopsies. Muscle carnitine rose 21 percent, and work output in a 30-minute performance trial rose 11 percent from baseline. Muscle carnitine only rose with the carbohydrate, because insulin drives it into muscle, and only over months.

It is a cofactor, not a driver: having more carnitine does not make the body burn more fat than its energy demand calls for.

A great deal by the standards of this category. Three meta-analyses of randomised trials have been published (Obesity Reviews 2016, nine trials; Pharmacological Research 2020, 43 trials; Clinical Nutrition ESPEN 2020, 37 trials). They report a modest effect on body weight in overweight adults who were also changing diet and activity, with the effect shrinking the longer a trial ran and no consistent change in body-fat percentage or waist circumference. Nearly every trial used oral carnitine at gram doses. There are no randomised trials of low-dose intramuscular L-carnitine in healthy adults, so what the injection does in that group is extrapolated rather than measured.

L-carnitine suits someone who is training and wants a cofactor for the fuel pathway training uses, often described by prescribers around training tolerance and recovery between sessions. It is a common add-on to a weight program, including alongside a GLP-1, and it has the longer safety record of the two. L-carnitine vs GLP-1 covers that pairing.

AOD-9604 suits someone who is already training and eating well, wants a fat-focused signal that leaves appetite and the growth hormone axis alone, and understands the human obesity trials were negative. It is also part of the SHRED and PHYSIQ blends.

Because they are described at different steps, some physicians prescribe both. No study has tested the combination, and no Pepti product contains both. They are separate vials with separate injection types, so never mix them in one syringe. Starting on different dates makes it easier to tell which one caused any change.